Market closedNon-fractional
Allogene Therapeutics/ALLO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Allogene Therapeutics
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
Ticker
ALLO
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
South San Francisco, United States
Employees
233
Website
www.allogene.com
ALLO Metrics
BasicAdvanced
$608M
Market cap
-
P/E ratio
-$1.79
EPS
0.90
Beta
-
Dividend rate
Price and volume
Market cap
$608M
Beta
0.9
Financial strength
Current ratio
12.797
Quick ratio
12.512
Long term debt to equity
19.272
Total debt to equity
20.774
Management effectiveness
Return on assets (TTM)
-26.71%
Return on equity (TTM)
-55.48%
Valuation
Price to revenue (TTM)
5,459.662
Price to book
1.07
Price to tangible book (TTM)
1.07
Price to free cash flow (TTM)
-2.086
Growth
Revenue change (TTM)
-30.40%
Earnings per share change (TTM)
-28.43%
3-year revenue growth (CAGR)
-86.86%
3-year earnings per share growth (CAGR)
-0.38%
What the Analysts think about ALLO
Analyst Ratings
Majority rating from 18 analysts.
ALLO Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$65M
-80.13%
Profit margin
0.00%
NaN%
ALLO Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.53
-$0.37
-$0.51
-$0.38
-
Expected
-$0.59
-$0.52
-$0.45
-$0.41
-$0.35
Surprise
-10.01%
-28.78%
13.55%
-7.17%
-
ALLO News
AllArticlesVideos
Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)
GlobeNewsWire·4 weeks ago
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
GlobeNewsWire·1 month ago
Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products
Seeking Alpha·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Allogene Therapeutics stock?
Allogene Therapeutics (ALLO) has a market cap of $608M as of July 27, 2024.
What is the P/E ratio for Allogene Therapeutics stock?
The price to earnings (P/E) ratio for Allogene Therapeutics (ALLO) stock is 0 as of July 27, 2024.
Does Allogene Therapeutics stock pay dividends?
No, Allogene Therapeutics (ALLO) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Allogene Therapeutics dividend payment date?
Allogene Therapeutics (ALLO) stock does not pay dividends to its shareholders.
What is the beta indicator for Allogene Therapeutics?
Allogene Therapeutics (ALLO) has a beta rating of 0.9. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Allogene Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.